ESC 2024 - FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease
Use of semaglutide 1.0 mg (Ozempic) offers benefits on cardiovascular outcomes, regardless of baseline chronic kidney disease severity, according to an analysis of the FLOW trial presented at the European Society of Cardiology (ESC) Congress 2024.
Presented by Kenneth Mahaffey, MD, professor of Medicine at Stanford University, less than 4 months after the FLOW trial headlined the European Renal Association Congress, the latest analysis of FLOW provides evidence of the effects of the GLP-1 receptor agonist using different definitions of kidney disease severity.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
